Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Condition: Hepatocellular Carcinoma Interventions: Drug: Anlotinib; Device: TACE+RFA Sponsor: Jinglong Chen Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials